Vaccines that don't need refrigeration successfully trialled in UK

A groundbreaking clinical trial in the UK has successfully tested a "fridge-free" vaccine, offering a potential solution to the significant global issue of vaccine wastage. Most vaccines currently require strict temperature control throughout their journey from manufacture to administration, a process known as the "cold chain."

However, this reliance on refrigeration presents major challenges, particularly in developing countries, remote areas, or conflict zones where reliable electricity and cold storage are scarce. It is estimated that around half of all vaccines produced globally are wasted each year, often due to temperature fluctuations during transport or storage.

Researchers at the UK's National Institute for Health and Care Research (NIHR) have developed a novel approach inspired by resurrection plants. These plants can survive extreme drought by producing a sugar called trehalose, which stabilizes their cells. The scientists used this principle to convert a liquid tetanus-diphtheria vaccine into a dry powder form, stabilized with trehalose, which remained viable for a year at room temperature before being reconstituted with water for injection.

“

equivalent immune responses to the conventional vaccine as well as being safe and well tolerated

Early-stage studies involving 60 volunteers showed that the "fridge-free" vaccine elicited an "equivalent" immune response to the conventional version and was found to be "safe and well tolerated." Prof. Saul Faust, director of the NIHR Clinical Research Facility in Southampton, highlighted the potential of this technology to "remove cold chain dependence, reduce wastage and improve access."

A larger trial with 160 participants is planned to further validate the findings. The research aims to meet the World Health Organization's goal of developing vaccines that can withstand temperatures of 30C and 75% relative humidity, with data suggesting this new vaccine can also survive temperature cycling between -20C and +40C. This could revolutionize vaccine distribution, allowing for easier transport and storage in diverse environmental conditions.

“

This obviously has potential to remove cold chain dependence, reduce wastage and improve access.